DENNIS DOBARD: Open Payments
NPI 1063554038 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,812 in 154 payments from 16 companies in 2025. Trend: 2023 $2,279 · 2024 $2,438 · 2025 $2,812
Food & beverage: $2,742Education: $70
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $351 |
| Teva Pharmaceuticals USA, Inc. | 13 | $338 |
| Supernus Pharmaceuticals, Inc. | 18 | $320 |
| E.R. Squibb & Sons, L.L.C. | 18 | $311 |
| Neurocrine BioSciences, Inc. | 14 | $268 |
| Alkermes, Inc. | 14 | $253 |
| Axsome Therapeutics, Inc. | 5 | $214 |
| Vanda Pharmaceuticals Inc. | 16 | $194 |
| Janssen Pharmaceuticals, Inc | 10 | $157 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $141 |
Products named: Qelbree, COBENFY, INGREZZA, ARISTADA, REXULTI, Auvelity, AUSTEDO XR, ABILIFY ASIMTUFII.
Industry payments across MO — which companies pay providers there.
